Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

MAHA Report's Fake Citations A Red Flag For Experts No Photo Available

Yeji Jesse Lee

Fake and misinterpreted citations in a recent federal report focused on chronic disease in the U.S. are raising alarm bells that feder... (more story)

Health Policy Expert On The Changing Vaccine Landscape No Photo Available

Yeji Jesse Lee

KFF's Jen Kates talks about the changing vaccine landscape, the trickle-down effects of the Trump administration's policies and what s... (more story)

Monthly Merger Review Snapshot No Photo Available

Matthew Perlman

The Federal Trade Commission finally dropped its long-pending challenge of Microsoft's purchase of video game developer Activision Bli... (more story)